DATABASE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

EPRX — Eupraxia Pharmaceuticals Inc.

EPRX (Eupraxia Pharmaceuticals Inc.) stock: $8.53, $562.2M market cap, $80.6M cash, $481.6M EV, $646.5M fully diluted market cap. Next expected readout: Dec-26. Lead program: EP-104GI (Eosinophilic Esophagitis), Phase 2. Data from Fully Diluted's biotech stocks database.

Share price
$8.53
Market cap
$562.2M
Cash
$80.6M
Enterprise value
$481.6M

Balance sheet

Cash$80.6M
Debt$0.0M
Net cash$80.6M
Enterprise value$481.6M
Basic shares65.9M shares
Fully diluted shares75.8M shares
Fully diluted market cap$646.5M
Cash per share$1.22

Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.

Price history

Loading EPRX daily closes…

Loading price history…

Upcoming catalysts

ExpectedDrugPhaseIndicationMgmt guide
Jan 12 - Feb 23EP-104GIPhase 2Eosinophilic EsophagitisQ4 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.
Subscribe to Compounding Ego